Characterization of a Bacteriophage GEC_vB_Bfr_UZM3 Active against Bacteroides fragilis

Nata Bakuradze; Maia Merabishvili; Ia Kusradze; Pieter Jan Ceyssens; Jolien Onsea; Willem Jan Metsemakers; Nino Grdzelishvili; Guliko Natroshvili; Tamar Tatrishvili; Davit Lazvliashvili; Nunu Mitskevich; Jean Paul Pirnay; Nina Chanishvili

doi:10.3390/v15051042

Characterization of a Bacteriophage GEC_vB_Bfr_UZM3 Active against Bacteroides fragilis

Nata Bakuradze, Maia Merabishvili, Ia Kusradze, Pieter Jan Ceyssens, Jolien Onsea, Willem Jan Metsemakers, Nino Grdzelishvili, Guliko Natroshvili, Tamar Tatrishvili, Davit Lazvliashvili, Nunu Mitskevich, Jean Paul Pirnay, Nina Chanishvili

Lab MCT

Research output: Contribution to journal › Article › peer-review

Abstract

Bacteroides fragilis is a commensal gut bacterium that is associated with a number of blood and tissue infections. It has not yet been recognized as one of the drug-resistant human pathogens, but cases of the refractory infections, caused by strains that are not susceptible to the common antibiotic regimes established for B. fragilis, have been more frequently reported. Bacteriophages (phages) were found to be a successful antibacterial alternative to antibiotic therapy in many cases of multidrug-resistant (MDR) bacterial infections. We have characterized the bacteriophage GEC_vB_Bfr_UZM3 (UZM3), which was used for the treatment of a patient with a chronic osteomyelitis caused by a B. fragilis mixed infection. Studied biological and morphological properties of UZM3 showed that it seems to represent a strictly lytic phage belonging to a siphovirus morphotype. It is characterized by high stability at body temperature and in pH environments for about 6 h. Whole genome sequencing analysis of the phage UZM3 showed that it does not harbor any known virulence genes and can be considered as a potential therapeutic phage to be used against B. fragilis infections.

Original language	English
Article number	1042
Journal	Viruses
Volume	15
Issue number	5
DOIs	https://doi.org/10.3390/v15051042
Publication status	Published - May 2023

Keywords

Bacteroides fragilis
bacteriophage
phage therapy

Access to Document

10.3390/v15051042

Cite this

Bakuradze, N., Merabishvili, M., Kusradze, I., Ceyssens, P. J., Onsea, J., Metsemakers, W. J., Grdzelishvili, N., Natroshvili, G., Tatrishvili, T., Lazvliashvili, D., Mitskevich, N., Pirnay, J. P., & Chanishvili, N. (2023). Characterization of a Bacteriophage GEC_vB_Bfr_UZM3 Active against Bacteroides fragilis. Viruses, 15(5), Article 1042. https://doi.org/10.3390/v15051042

@article{cf5c2bd6e6c445c8a12e4555504c013d,

title = "Characterization of a Bacteriophage GEC_vB_Bfr_UZM3 Active against Bacteroides fragilis",

abstract = "Bacteroides fragilis is a commensal gut bacterium that is associated with a number of blood and tissue infections. It has not yet been recognized as one of the drug-resistant human pathogens, but cases of the refractory infections, caused by strains that are not susceptible to the common antibiotic regimes established for B. fragilis, have been more frequently reported. Bacteriophages (phages) were found to be a successful antibacterial alternative to antibiotic therapy in many cases of multidrug-resistant (MDR) bacterial infections. We have characterized the bacteriophage GEC_vB_Bfr_UZM3 (UZM3), which was used for the treatment of a patient with a chronic osteomyelitis caused by a B. fragilis mixed infection. Studied biological and morphological properties of UZM3 showed that it seems to represent a strictly lytic phage belonging to a siphovirus morphotype. It is characterized by high stability at body temperature and in pH environments for about 6 h. Whole genome sequencing analysis of the phage UZM3 showed that it does not harbor any known virulence genes and can be considered as a potential therapeutic phage to be used against B. fragilis infections.",

keywords = "Bacteroides fragilis, bacteriophage, phage therapy",

author = "Nata Bakuradze and Maia Merabishvili and Ia Kusradze and Ceyssens, {Pieter Jan} and Jolien Onsea and Metsemakers, {Willem Jan} and Nino Grdzelishvili and Guliko Natroshvili and Tamar Tatrishvili and Davit Lazvliashvili and Nunu Mitskevich and Pirnay, {Jean Paul} and Nina Chanishvili",

note = "Publisher Copyright: {\textcopyright} 2023 by the authors.",

year = "2023",

month = may,

doi = "10.3390/v15051042",

language = "English",

volume = "15",

journal = "Viruses",

issn = "1999-4915",

number = "5",

}

TY - JOUR

T1 - Characterization of a Bacteriophage GEC_vB_Bfr_UZM3 Active against Bacteroides fragilis

AU - Bakuradze, Nata

AU - Merabishvili, Maia

AU - Kusradze, Ia

AU - Ceyssens, Pieter Jan

AU - Onsea, Jolien

AU - Metsemakers, Willem Jan

AU - Grdzelishvili, Nino

AU - Natroshvili, Guliko

AU - Tatrishvili, Tamar

AU - Lazvliashvili, Davit

AU - Mitskevich, Nunu

AU - Pirnay, Jean Paul

AU - Chanishvili, Nina

PY - 2023/5

Y1 - 2023/5

N2 - Bacteroides fragilis is a commensal gut bacterium that is associated with a number of blood and tissue infections. It has not yet been recognized as one of the drug-resistant human pathogens, but cases of the refractory infections, caused by strains that are not susceptible to the common antibiotic regimes established for B. fragilis, have been more frequently reported. Bacteriophages (phages) were found to be a successful antibacterial alternative to antibiotic therapy in many cases of multidrug-resistant (MDR) bacterial infections. We have characterized the bacteriophage GEC_vB_Bfr_UZM3 (UZM3), which was used for the treatment of a patient with a chronic osteomyelitis caused by a B. fragilis mixed infection. Studied biological and morphological properties of UZM3 showed that it seems to represent a strictly lytic phage belonging to a siphovirus morphotype. It is characterized by high stability at body temperature and in pH environments for about 6 h. Whole genome sequencing analysis of the phage UZM3 showed that it does not harbor any known virulence genes and can be considered as a potential therapeutic phage to be used against B. fragilis infections.

AB - Bacteroides fragilis is a commensal gut bacterium that is associated with a number of blood and tissue infections. It has not yet been recognized as one of the drug-resistant human pathogens, but cases of the refractory infections, caused by strains that are not susceptible to the common antibiotic regimes established for B. fragilis, have been more frequently reported. Bacteriophages (phages) were found to be a successful antibacterial alternative to antibiotic therapy in many cases of multidrug-resistant (MDR) bacterial infections. We have characterized the bacteriophage GEC_vB_Bfr_UZM3 (UZM3), which was used for the treatment of a patient with a chronic osteomyelitis caused by a B. fragilis mixed infection. Studied biological and morphological properties of UZM3 showed that it seems to represent a strictly lytic phage belonging to a siphovirus morphotype. It is characterized by high stability at body temperature and in pH environments for about 6 h. Whole genome sequencing analysis of the phage UZM3 showed that it does not harbor any known virulence genes and can be considered as a potential therapeutic phage to be used against B. fragilis infections.

KW - Bacteroides fragilis

KW - bacteriophage

KW - phage therapy

UR - http://www.scopus.com/inward/record.url?scp=85160374839&partnerID=8YFLogxK

U2 - 10.3390/v15051042

DO - 10.3390/v15051042

M3 - Article

C2 - 37243129

AN - SCOPUS:85160374839

SN - 1999-4915

VL - 15

JO - Viruses

JF - Viruses

IS - 5

M1 - 1042

ER -

Characterization of a Bacteriophage GEC_vB_Bfr_UZM3 Active against Bacteroides fragilis

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this